Breakthrough COPD Treatment Awaits FDA Approval, Promising Major Market Impact

  ()
Verona Pharma is poised for a pivotal breakthrough with its drug candidate, ensifentrine, potentially transforming COPD treatment pending an upcoming FDA decision. Read on for more.
Tags: Biotechnology / Pharmaceuticals

Critical Reforms Stuck in Congressional Gridlock

Contributed Opinion
  ()
McAlinden Research shares its thoughts on the current state of the cannabis market in light of recent legislative moves and two ETFs that may be impacted.
Tags: Cannabis

Medical School Renews Contract with Tech Co.

  ()
This move further validates the firm's Medical Education Suite. Discover why one analyst rates this healthcare-disrupting company as a Strong Buy.
Tags: Healthcare ServicesTechnology

Biotech Co. Positioned for Ensifentrine Approval, Analyst Says

Research Report
  ()
According to a Jefferies & Co. research note, Verona Pharma Plc. has a 90-95% probability of success for PDUFA approval.
Tags: Biotechnology / Pharmaceuticals

Pharma's Promising Path in COPD Treatment

  ()
As Verona Pharma releases more news surrounding its COPD treatments, analysts are taking notice. Read to see what Verona is doing in the pharmaceutical space and what three analysts have to say about this company's stock.
Tags: Biotechnology / Pharmaceuticals

PDUFA Date Coming Up for U.K. Biopharma

Research Report
  ()
The company has a commercialization plan in place and is preparing further for approval, noted a Canaccord Genuity report.
Tags: Biotechnology / Pharmaceuticals

Biopharma's New Drug for COPD Likely to be Approved

Research Report
  ()
Characteristics of the Buy-rated company's lead candidate make it "an intriguing commercial prospect," noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

AI Healthcare Stock Has Bullish Setup, Expert Says

Contributed Opinion
  ()
Technical Analyst Clive Maund reviews Treatment.com AI's charts and the recent influx of news to explain why he believes it is a Strong Buy.
Tags: Life Sciences Tools & Diagnostics

New AI Solutions Set To Transform Medical Education and Clinical Practice

  ()
Treatment.com AI Inc., a leader in artificial intelligence for healthcare education, has introduced two new tools for its Medical Education Suite (MES).
Tags: Healthcare Services

Analyst Says Pharma Co. Has No True Competitor

Research Report
  ()
Verona Pharma Plc. recently is gearing up for a potential FDA approval of its twice-daily ensifentrine, according to a Jefferies & Co. research note.
Tags: Biotechnology / Pharmaceuticals

LA Biotech's Lower Revenue Will Be Short Lived

Research Report
  ()
While Ontrak Inc. may have had a loss in revenue in 2023, this will be short-lived, according to a Roth MKM research note.
Tags: Biotechnology / Pharmaceuticals

Healthcare Co. Welcomes Possible AI Funding Effort in Canada

  ()
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.
Tags: Life Sciences Tools & DiagnosticsMedical DevicesHealthcare ServicesTechnology

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out

  ()
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.
Tags: Biotechnology / PharmaceuticalsGoldOil & Gas - Exploration & ProductionSilver

Co. Adding 500 Patients to Its Mental Health Care Platform

  ()
This Canada-based health care technology firm is profitable and growing. Learn more about it here.
Tags: Healthcare Services

Analyst Encouraged by ON Gov's Decision To Sustain Fees

Research Report
  ()
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.
Tags: Healthcare Services

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock

  ()
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
Tags:  Biotechnology / Pharmaceuticals

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

AI Co. Funded To Develop AI Approach to Health Equity

  ()
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
Tags:  Healthcare ServicesLife Sciences Tools & Diagnostics

Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says

Research Report
  ()
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.
Tags:  Healthcare Services

AI Medical App Passes Standard Student Test

  ()
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector.
Tags:  Life Sciences Tools & Diagnostics

Biotech Co.'s Target Price Significantly Higher Than Current

Research Report
  ()
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
Tags:  Biotechnology / Pharmaceuticals

Biotech Stocks Break Out

Contributed Opinion
  ()
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
Tags:  Biotechnology / PharmaceuticalsMedical Devices